Simcere Enters into an Exclusive License Agreement with Connect Biopharm for Rademikibart
Shots:
- As per the terms of the agreement, Simcere is granted the exclusive rights to develop, manufacture, and market Rademikibart for all indications in Greater China. Outside of Greater China, Connect will maintain its rights & will also finish the ongoing clinical study for the treatment of AD
- Through this partnership, Simcere will expand its product portfolio in autoimmunology & strengthen the synergistic impact in its commercialization endeavors
- Rademikibart (CBP-201), completely humanized mAB targets IL-4Rα, & efficiently inhibit IL-4 and IL-13 activities, treating Th2-related inflammatory illnesses such as asthma & AD
Ref: PR Newswire | Image: Simcere
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
